Since the year began until May 31, medicines associated with diabetes and cardiovascular disease pathologies are the best selling in Spanish pharmacies.In addition, among the top ten molecules that were most prescribed in the first five months of the year almost 600 million euros were spent.
The first of this list, according to the data obtained exclusively by this means of the IQVIA consultant, is Eliquis, an anticoagulant that markens the pharmaceutical Bristol Myers Squibb.The company has entered 118.6 million euros for this medicine in five months, 17.71% more than in the same period of 2021.
The next two drugs on the list are Ozempic and Xarelto.The first is marketed by Novo Nordisk and obtained sales of 83.4 million euros.This is the best -selling antidiabetic in Spain that also grew in income compared to the first five months of 2021 by 53.1%.At a time of course, Xarelto, marketed by Bayer, is another anticoagulant indicated for cardiovascular diseases.Until May 31, he raised 80.4 million euros (8.48% more).
They complete the 'top five' other diabetic medicine and another anticoagulant.The first of them, Trulicity, is marketed by Lilly and obtained income of 64.3 million euros (16% more).For its part, the pharmacist Daiichi Sankyo obtained fifth place with its drug, marketed under the name of Lixiana, with sales of 58.6 million euros.
Among the last five positions of the ten best -selling medications in Spanish pharmacies are three other antidiabetics, one for heart failure and another for osteoporosis, the only pathology that escapes the common norm.Boehringer markets the antidiabetic Jardiance, which obtained sales of 57.4 million euros, 44% more.This growth, along with Ozempic's are the largest among this ten molecules.
In the seventh place it is entruesto, by Novartis.This medicine, indicated for LAN cardiovascular insufficiency, obtained sales of 53.1 million euros, 22% more than in the first five months of 2021. Together behind it is prolia, indicated for osteoporosis and that obtained sales by valueof 50 million euros (9.5% more).Two other diabetes medications, Toujeo (Sanofi) and Synjardy (Boehringer/Lilly).Each of them obtained just over 45 million euros, starring in a growth of 37.2%.
In total, spending on Spanish pharmacies in the first five months of the year, including any medication for which recipe is needed, amounted to 7,194 million euros, 8.1% more.It is a new increase in the bill of public administrations.
